Sertraline
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neurodevelopmental Disorders
Conditions
Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder, Fragile X Syndrome, Tuberous Sclerosis, 22Q11 Deletion Syndrome, 22Q11 Deletion, ADHD, Tic Disorders, Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence, ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive, Anxiety, Anxiety Disorders
Trial Timeline
Sep 16, 2024 → Sep 1, 2026
NCT ID
NCT06081348About Sertraline
Sertraline is a phase 2 stage product being developed by Brain Biotech for Neurodevelopmental Disorders. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06081348. Target conditions include Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06081348 | Phase 2 | Recruiting |
| NCT00208585 | Pre-clinical | UNKNOWN |